United States Head and Neck Squamous Cell Carcinoma Market 2025 | Growth Drivers, Competitive Landscape & Investment Opportunities

Market Size and Growth

Global Head and Neck Squamous Cell Carcinoma Market reached US$ 2.2 billion in 2022 and is expected to reach US$ 4.3 billion by 2030 growing with a CAGR of 8.8% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In October 2025, the FDA approved an expanded use of Regeneron Pharmaceuticals' immunotherapy drug Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), following surgery and radiation. Clinical trials showed a 68% reduction in the risk of cancer recurrence or death compared to placebo.

✅ In June 2025, the FDA approved the use of an immunotherapy drug for the treatment of locally advanced head and neck squamous cell carcinoma, based on a clinical trial co-led by MSK's Nancy Lee, MD.

✅ In May 2025, Merus presented data showing that combining its experimental agent petosemtamab with Keytruda in untreated HNSCC yielded a 1-year overall survival (OS) of ~79%, outperforming Keytruda alone (~44%) and other competitor therapies.

Recent Industry Developments

✅ In July 2025, a Phase Ib trial in Japan (jRCT2011240074) was registered to test BI-770371 + pembrolizumab ± cetuximab vs pembrolizumab monotherapy as first-line treatment in metastatic/recurrent HNSCC, signaling further investment into novel combinations.

✅ In May 2025, Rakuten Medical expanded its global Phase 3 trial (ASP-1929-381 / "ECLIPSE") of ASP-1929 photoimmunotherapy + pembrolizumab as first-line treatment for recurrent HNSCC to include patient recruitment in Japan, accelerating geographic reach.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/head-and-neck-squamous-cell-carcinoma-market?sb

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer arising from the squamous cells lining the mucosal surfaces of the head and neck, including the oral cavity, throat, and larynx. Treatments include surgery, radiation, chemotherapy, and immunotherapy, aiming to control tumor growth, preserve function, and improve patient survival.

Recent Mergers and acquisitions:

United States: Recent M&A Developments

✅ In September 2025, Genmab announced its acquisition of Merus N.V. for $8 billion in an all-cash deal. This strategic move aims to bolster Genmab's oncology pipeline, particularly enhancing its bispecific antibody portfolio. Merus' lead asset, petosemtamab, is currently in Phase 3 trials for HNSCC and has received two FDA Breakthrough Therapy Designations. The acquisition is set to close in Q1 2026 and is expected to significantly accelerate the development and commercialization of innovative therapies for HNSCC patients.

Japan: Recent M&A Developments

✅ In September 2025, Merck KGaA, Darmstadt, Germany, entered into a licensing agreement with Debiopharm for the exclusive rights to develop and commercialize xevinapant, a promising therapy for HNSCC. The deal includes an upfront payment of $237 million, with potential milestones and royalties, bringing the total deal value to over $1 billion. This partnership underscores Merck KGaA's commitment to expanding its oncology portfolio and advancing treatment options for HNSCC patients.

Key Players:

=> Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH., GSK plc, Novartis AG, Bayer AG, Merck & Co., Inc., AstraZeneca, Eli Lilly and Co, and Cipla Inc. among others.

Growth Forecast Projected:

The Global Head and Neck Squamous Cell Carcinoma Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Head and Neck Squamous Cell Carcinoma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=head-and-neck-squamous-cell-carcinoma-market

Key Segments:

➥ By Type: Salivary Gland, Oral and Oropharyngeal, Nasal Cavity & Paranasal Sinuses, Nasopharyngeal, Laryngeal, Hypopharyngeal

➥ By Drug Class: EGFR Inhibitors, Immune Checkpoint Inhibitors, Others

➥ By Route of Administration: Intravenous, Oral, Others

➥ By Treatment: Radiation, Chemotherapy, Immunotherapy

➥ By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Regional Analysis for Head and Neck Squamous Cell Carcinoma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Head and Neck Squamous Cell Carcinoma producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Head and Neck Squamous Cell Carcinoma revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/head-and-neck-squamous-cell-carcinoma-market?sb

FAQ

What is the current size of the Head and Neck Squamous Cell Carcinoma Market?

A: In 2022, the Head and Neck Squamous Cell Carcinoma Market was valued at US$ 2.2 billion, reflecting its strong industry presence.

Q2: How large is the Head and Neck Squamous Cell Carcinoma Market expected to be by 2030?

A: By 2030, industry forecasts suggest the Head and Neck Squamous Cell Carcinoma Market will grow to around US$ 4.3 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Head and Neck Squamous Cell Carcinoma Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.